News

A live parasite vaccine for deadly leishmaniasis

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.
Written byStephanie DeMarco, PhD
| 4 min read
Leishmania mexicana parasites in the promastigote stage

Leishmania mexicana parasites in the promastigote stage

University of Oxford, Richard Wheeler

Working as a medical intern in his home country of India, Abhay Satoskar had seen many cases like the one in front of him. A young child had been rushed into the emergency room, having collapsed while playing on the playground. When the doctors found that the youth’s spleen had ruptured, there was very little they could do.

Satoskar and his fellow physicians soon discovered that the child had been suffering from visceral leishmaniasis, a deadly disease caused by the parasite Leishmania donovani, which is transmitted to humans via the bite of a blood-feeding sandfly.

“This was something preventable if you had the right interventions around,” said Satoskar, now an immunologist at Ohio State University. Drugs for leishmaniasis, however, can be toxic and are losing effectiveness due to increasing resistance. The real key to halting this deadly disease is vaccines, but so far, there are no approved vaccines for leishmaniasis.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Stephanie DeMarco, PhD Headshot

    Stephanie joined Drug Discovery News as an Assistant Editor in 2021. She earned her PhD from the University of California Los Angeles in 2019 and has written for Discover Magazine, Quanta Magazine, and the Los Angeles Times. As an assistant editor at DDN, she writes about how microbes influence health to how art can change the brain. When not writing, Stephanie enjoys tap dancing and perfecting her pasta carbonara recipe.

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.